Including TargetCancer Cholangiocarcinoma Cell Line Bank At MGH And Expansion Into Esophageal Cancer Research
NEW YORK--(BUSINESS WIRE)-- TargetCancer, a non-profit organization dedicated to promoting the development of lifesaving treatment protocols for rare cancers, is proud to announce over $70,000 in new grants to fund rare cancer research.
“We are enormously proud to announce these new grants today. Only two and a half years ago, our founder Paul Poth awarded TargetCancer's first grant of $7,500 and today we announce $73,000 to support critical rare cancer research,” explained Kristen Palma Poth, wife of Paul Poth and President of TargetCancer. “This research will have a profound impact on the treatment of diseases that have been overlooked for too long.”
Creation of cholangiocarcinoma cell line bank
TargetCancer awarded a $32,000 grant to create the TargetCancer Cholangiocarcinoma Cell Line Bank at Massachusetts General Hospital (MGH). This unique and innovative initiative unites researchers, surgeons, clinicians, and pathologists towards the goal of extracting and preserving critical cholangiocarcinoma (bile duct cancer) cell line samples that are essential to finding treatments.
Continued commitment to cholangiocarcinoma research
TargetCancer continues its commitment to cholangiocarcinoma research with $20,000 in additional funding to Dr. Nabeel Bardeesy’s lab at the Massachusetts General Hospital Cancer Center. This builds on TargetCancer’s grant of $40,000 in 2011 to support Dr. Bardeesy’s groundbreaking research into cholangiocarcinoma.
Expansion to esophageal cancer research
TargetCancer has expanded its research funding to a new rare cancer type with a $10,000 grant to support Dr. Adam Bass’ esophageal cancer research at the Dana-Farber Cancer Institute. Dr. Bass is a leader in cancer genomics, and his current project is the largest genomic study of esophageal cancer ever attempted.
Harvard Medical School fellowships
With an $8,300 grant, TargetCancer funded the second year of its three year commitment to the TargetCancer Medical Student Fund at Harvard Medical School. This fellowship supports the summer studies of two students interested in researching rare cancers.
Launched in 2009 by Cambridge, MA resident Paul Poth, TargetCancer promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations and raising awareness among scientists, clinicians and patients.
When Paul, a dedicated husband, new father and a lawyer with a passion for public service was diagnosed with cholangiocarcinoma, he quickly learned that there was no real insight into the disease or its treatments. Due to lack of funds and research, Paul had no choice but to follow his doctors’ plans to patch together treatments for other forms of cancers.
Sadly, Paul did not survive this cancer, but he knew treatment for rare cancers does not have to be this way. After Paul’s passing, his wife, friends and family continued TargetCancer, in honor and celebration of Paul.
100% of donations directly fund TargetCancer’s research initiatives- all overhead and expenses are covered by sponsorships or reimbursement by TargetCancer’s Board of Directors.
Please visit www.targetcancer.info for much more information on all of these initiatives.
For more information on TargetCancer and their initatives or to set up an interview, please contact:
Pamela Lipshitz; [email protected]
(o) 212-256-0592; (c) 917-859-6852
Pamela Lipshitz, 212-256-0592
KEYWORDS: United States North America Massachusetts New York
INDUSTRY KEYWORDS: Stem Cells Education University Health Biotechnology Clinical Trials Hospitals Oncology Philanthropy Research Science Foundation